soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025 Reduces CV Events in T2DM – (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine 🧪 T2DM + ASCVD/CKD 💊 Oral semaglutide 14 mg vs placebo 📉 📌 Most viewed this week

Many clients report feeling more emotionally balanced and less fatigued under daily pressures after consistent treatments

Livovsky DM, Azpiroz F (2021) Gastrointestinal Contributions to the Postprandial Experience

They affect approximately 1 in 10 people in the UK at some point in their lives, with men being more commonly affected than women

March 13, 2026: FDA Sends Warning Letter to Novo Nordisk The FDA has sent a warning letter to the maker of Ozempic and Wegovy over a potential failure to report side effects connected to these drugs

doi: 10.1016/j.tcb.2014.04.002

I was so excited to have my anti age treatment this morning